Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics

Abstract Within an institutional pharmacogenomics implementation program, we surveyed 463 outpatients completing preemptive pharmacogenomic testing whose genetic results were available to providers for guiding medication treatment. We compared views and experiences from self-reported White and Black...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Loren Saulsberry, Keith Danahey, Brittany A. Borden, Elizabeth Lipschultz, Maimouna Traore, Mark J. Ratain, David O. Meltzer, Peter H. O’Donnell
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Genetics QH426-470
Acceso en línea:	https://doaj.org/article/3f295504c3594666b622a54863c65a46
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3f295504c3594666b622a54863c65a46
record_format	dspace
spelling	oai:doaj.org-article:3f295504c3594666b622a54863c65a462021-11-08T11:19:27ZUnderrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics10.1038/s41525-021-00253-12056-7944https://doaj.org/article/3f295504c3594666b622a54863c65a462021-11-01T00:00:00Zhttps://doi.org/10.1038/s41525-021-00253-1https://doaj.org/toc/2056-7944Abstract Within an institutional pharmacogenomics implementation program, we surveyed 463 outpatients completing preemptive pharmacogenomic testing whose genetic results were available to providers for guiding medication treatment. We compared views and experiences from self-reported White and Black patients, including education level as a covariate across analyses. Black patients were less confident about whether their providers made personalized treatment decisions, and overwhelmingly wanted a greater role for their genetic information in clinical care. Both groups similarly reported that providers asked their opinions regarding medication changes, but White patients were more likely (59% vs. 49%, P = 0.005) to discuss the impact of personal/genetic makeup on medication response with providers, and Black patients reported initiating such discussions much less frequently (4% vs. 15%, P = 0.037). Opportunities exist for enhanced communication with underrepresented patients around personalized care. Tailored communication strategies and development of support tools employed in diverse healthcare settings may facilitate pharmacogenomically guided medication treatment that equitably benefits minority patient populations.Loren SaulsberryKeith DanaheyBrittany A. BordenElizabeth LipschultzMaimouna TraoreMark J. RatainDavid O. MeltzerPeter H. O’DonnellNature PortfolioarticleMedicineRGeneticsQH426-470ENnpj Genomic Medicine, Vol 6, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Genetics QH426-470
spellingShingle	Medicine R Genetics QH426-470 Loren Saulsberry Keith Danahey Brittany A. Borden Elizabeth Lipschultz Maimouna Traore Mark J. Ratain David O. Meltzer Peter H. O’Donnell Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics
description	Abstract Within an institutional pharmacogenomics implementation program, we surveyed 463 outpatients completing preemptive pharmacogenomic testing whose genetic results were available to providers for guiding medication treatment. We compared views and experiences from self-reported White and Black patients, including education level as a covariate across analyses. Black patients were less confident about whether their providers made personalized treatment decisions, and overwhelmingly wanted a greater role for their genetic information in clinical care. Both groups similarly reported that providers asked their opinions regarding medication changes, but White patients were more likely (59% vs. 49%, P = 0.005) to discuss the impact of personal/genetic makeup on medication response with providers, and Black patients reported initiating such discussions much less frequently (4% vs. 15%, P = 0.037). Opportunities exist for enhanced communication with underrepresented patients around personalized care. Tailored communication strategies and development of support tools employed in diverse healthcare settings may facilitate pharmacogenomically guided medication treatment that equitably benefits minority patient populations.
format	article
author	Loren Saulsberry Keith Danahey Brittany A. Borden Elizabeth Lipschultz Maimouna Traore Mark J. Ratain David O. Meltzer Peter H. O’Donnell
author_facet	Loren Saulsberry Keith Danahey Brittany A. Borden Elizabeth Lipschultz Maimouna Traore Mark J. Ratain David O. Meltzer Peter H. O’Donnell
author_sort	Loren Saulsberry
title	Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics
title_short	Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics
title_full	Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics
title_fullStr	Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics
title_full_unstemmed	Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics
title_sort	underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/3f295504c3594666b622a54863c65a46
work_keys_str_mv	AT lorensaulsberry underrepresentedpatientviewsandperceptionsofpersonalizedmedicationtreatmentthroughpharmacogenomics AT keithdanahey underrepresentedpatientviewsandperceptionsofpersonalizedmedicationtreatmentthroughpharmacogenomics AT brittanyaborden underrepresentedpatientviewsandperceptionsofpersonalizedmedicationtreatmentthroughpharmacogenomics AT elizabethlipschultz underrepresentedpatientviewsandperceptionsofpersonalizedmedicationtreatmentthroughpharmacogenomics AT maimounatraore underrepresentedpatientviewsandperceptionsofpersonalizedmedicationtreatmentthroughpharmacogenomics AT markjratain underrepresentedpatientviewsandperceptionsofpersonalizedmedicationtreatmentthroughpharmacogenomics AT davidomeltzer underrepresentedpatientviewsandperceptionsofpersonalizedmedicationtreatmentthroughpharmacogenomics AT peterhodonnell underrepresentedpatientviewsandperceptionsofpersonalizedmedicationtreatmentthroughpharmacogenomics
_version_	1718442226929893376

Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics

Ejemplares similares